Edition:
United States

Sanofi SA (SASY.PA)

SASY.PA on Paris Stock Exchange

68.77EUR
7:41am EDT
Change (% chg)

€0.83 (+1.22%)
Prev Close
€67.94
Open
€68.14
Day's High
€68.82
Day's Low
€68.05
Volume
904,198
Avg. Vol
2,484,703
52-wk High
€93.82
52-wk Low
€62.50

Latest Key Developments (Source: Significant Developments)

Sanofi files suit in U.S. to defend paten rights on Lantus and Lantus Solostar
Monday, 19 Sep 2016 01:00am EDT 

Sanofi : Files suit in U.S. To defend paten rights on Lantus and Lantus Solostar . Sanofi announced that it filed a patent infringement suit against Merck Sharp & Dohme Corp .Suit was triggered by a notification received from Merck in early August, in which Merck stated that it had filed an nda (505(b)(2) new drug application) with FDA for an insulin glargine drug product.  Full Article

Zealand Pharma announces new timelines for U.S. FDA decision on iglarlixi
Friday, 19 Aug 2016 06:28pm EDT 

Zealand Pharma A/S : Zealand announces new timelines for a U.S. FDA decision on iglarlixi, the fixed-ratio combination of lixisenatide (adlyxintm) and lantus(r), for the treatment of type 2 diabetes . Financial guidance for 2016 remains unchanged . A U.S. regulatory decision on iglarlixi is now expected before end of November 2016 .FDA requested updated information on pen delivery device for iglarlixi as part of new drug application, which was submitted by Sanofi.  Full Article

Sanofi, Pfizer, Gilead & Celgene interested in Medivation - CNBC citing sources
Friday, 29 Jul 2016 09:40am EDT 

: Sanofi, Pfizer, Gilead & Celgene interested in Medivation as company asks for indications of interest by mid-August - CNBC citing sources Further company coverage: [MDVN.O] (Bengaluru Newsroom: +1 646 223 8780).  Full Article

Sanofi says Brexit settlement must not impede drug regulation, approval processes
Friday, 29 Jul 2016 01:46am EDT 

Sanofi Chief Executive Olivier Brandicourt tells journalists during a conference call: Any Brexit settlement must not impede new drug regulation, approval process . "For the sake of patients and innovation, we need to ensure that Brexit does not negatively impact the regulatory capacity, the regulatory processes and the time frame for the introduction of new medicine both in the United Kingdom and in Europe, that must remain a priority," he said. Further company coverage: [SASY.PA] (Reporting by Matthias Blamont ; Editing by Andrew Callus) ((matthias.blamont@thomsonreuters.com;)).  Full Article

Sanofi pasteur ships seasonal influenza vaccine doses in U.S.
Tuesday, 26 Jul 2016 08:00am EDT 

Sanofi Pasteur : Ships First Of Its 2016 2017 seasonal influenza vaccine doses in United States .Sanofi pasteur plans to increase its supply to respond to shifting pediatric public health needs.  Full Article

Sanofi India June-qtr profit up about 33 pct
Friday, 22 Jul 2016 06:37am EDT 

Sanofi India Ltd : Says June-quarter net profit 853 million rupees . Says June-quarter net sales 5.65 billion rupees . Says net profit in June-quarter last year was 642 million rupees; net sales was 5.14 billion rupees . Declared interim dividend of 18 rupees per share .  Full Article

Sanofi Enzyme says Ontario adds LEMTRADA to exceptional access program for eligible patients
Thursday, 21 Jul 2016 08:00am EDT 

Sanofi SA:Ontario adds Lemtrada (Alemtuzumab) to exceptional access program for eligible patients.  Full Article

Sanofi Genzyme begins pivotal phase 2/3 trial
Wednesday, 6 Jul 2016 08:00am EDT 

Sanofi SA :Sanofi Genzyme begins pivotal phase 2/3 trial of olipudase alfa for adult patients with acid sphingomyelinase deficiency.  Full Article

Sanofi raises Medivation offer, enters confidentiality agreement
Tuesday, 5 Jul 2016 04:28pm EDT 

Sanofi statement: Sanofi confirms it has entered into a confidentiality agreement with Medivation under which it will be provided due diligence access and confidential information. . Says that it advised Medivation that upon signing a confidentiality agreement and being provided information, it would increase its offer to $58.00 in cash $3.00 in form of a contingent value right (cvr) relating to talazoparib sales performance. . Says a dataroom will be opened and management meetings scheduled in near term. . Under the confidentiality agreement, Sanofi has agreed to a customary standstill for six months subject to limited early termination events and has agreed to withdraw its consent solicitation. .Sanofi is confident that its due diligence can be quickly completed and that if an agreement is reached on a mutually acceptable transaction, Sanofi can close promptly given that it has received U.S. regulatory clearance, and there would be no financing condition..  Full Article

Sanofi Genzyme says Saskatchewan has added Lemtrada to province's MS drugs program
Tuesday, 5 Jul 2016 08:00am EDT 

Sanofi Sa :Saskatchewan has added Lemtrada to province's MS drugs program for eligible people living with relapsing-remitting multiple sclerosis.  Full Article

Fitch Affirms L'Oreal SA at 'F1+'

(The following statement was released by the rating agency) MILAN/LONDON, September 27 (Fitch) Fitch Ratings has affirmed L'Oreal SA's (L'Oreal) Short-Term Issuer Default Rating (IDR) and commercial paper (CP) programme at 'F1+'. The agency has also affirmed L'Oreal USA Inc's CP programme, guaranteed by L'Oreal, at 'F1+'. The ratings continue to reflect the company's strong market position and product portfolio as well as its robust geographical diversification. Also, L'Oreal continues to d